Literature DB >> 17329294

PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.

Simon J C Davies1, Martin S Lennard, Parviz Ghahramani, Peter Pratt, Andrea Robertson, John Potokar.   

Abstract

Medications are commonly prescribed to psychiatric inpatients on a PRN (pro re nata/as required) basis, allowing drugs to be administered on patient request or at nurses' discretion for psychiatric symptoms, treatment side effects or physical complaints. However, there has been no formal study of the pharmacokinetic implications of PRN prescribing. The objective of the study was to determine the prevalence of PRN drug prescription and administration, and to assess the potential for interactions involving CYP2D6 and CYP3A4 between drugs prescribed and administered to inpatients on psychiatry wards.A cross-sectional survey of prescriptions on general adult and functional elderly psychiatric wards in one city was carried out. Data were recorded from prescription charts of 323 inpatients (236 on general adult and 87 on functional elderly wards). Of 2089 prescriptions, 997 (48%) of prescriptions were on a PRN basis (most commonly benzodiazepines and other hypnotic agents, antipsychotics, analgesics and anticholinergic agents), but only 143 (14%) of these had been administered in the previous 24 hours. One fifth of patients were prescribed drug combinations interacting with CYP2D6 or CYP3A4 of potential clinical importance which included one or more drugs prescribed on a PRN basis.PRN prescribing is common among inpatients in psychiatry, and may lead to cytochrome P450 mediated interactions. Prescribers should be aware of the potential for unpredictability in plasma concentrations, side effects and efficacy which PRN prescribing may cause through these interactions, particularly in old age psychiatry and in treatment of acute psychosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329294     DOI: 10.1177/0269881107067242

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

1.  Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors:  Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

2.  Pro re nata (as needed) medication in nursing homes: the longer you stay, the more you get?

Authors:  Michael Dörks; Guido Schmiemann; Falk Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  2016-04-14       Impact factor: 2.953

3.  Demographic and clinical factors associated with benzodiazepine prescription at discharge from psychiatric inpatient treatment.

Authors:  Shannon M Peters; Kendra Quincy Knauf; Christina M Derbidge; Ryan Kimmel; Steven Vannoy
Journal:  Gen Hosp Psychiatry       Date:  2015-06-10       Impact factor: 3.238

4.  Pro re nata (as needed) psychotropic medication use in patients with borderline personality disorder and subjects with other personality disorders over 14 years of prospective follow-up.

Authors:  Eduardo Martinho; Garrett M Fitzmaurice; Frances R Frankenburg; Mary C Zanarini
Journal:  J Clin Psychopharmacol       Date:  2014-08       Impact factor: 3.153

Review 5.  Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review.

Authors:  Mojtaba Vaismoradi; Sara Amaniyan; Sue Jordan
Journal:  Pharmacy (Basel)       Date:  2018-08-29

6.  Practical Considerations of PRN Medicines Management: An Integrative Systematic Review.

Authors:  Abbas Mardani; Piret Paal; Christiane Weck; Shazia Jamshed; Mojtaba Vaismoradi
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

7.  Potentially Inappropriate Medication Use among Nursing Home Residents: Medication Errors Associated with Pro re nata Medications and the Importance of Pill Burden.

Authors:  Fatma Özge Kayhan Koçak; Emin Taşkıran; Zehra Kosuva Öztürk; Sevnaz Şahin
Journal:  Ann Geriatr Med Res       Date:  2022-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.